U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07159750) titled 'Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine' on Aug. 23.
Brief Summary: The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Study Start Date: Jan. 02, 2024
Study Type: OBSERVATIONAL
Condition:
Migraine
Episodic Migraine
Chronic Migraine, Headache
Intervention:
DRUG: CGRP antibody or gepant
Patients will s...